×
DaVita Receivables 2010-2024 | DVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DaVita receivables for the quarter ending September 30, 2024 were
$2.631B
, a
10.66% increase
year-over-year.
DaVita receivables for 2023 were
$2.416B
, a
5.28% decline
from 2022.
DaVita receivables for 2022 were
$2.551B
, a
5.81% increase
from 2021.
DaVita receivables for 2021 were
$2.411B
, a
1.16% decline
from 2020.
View More
DaVita Receivables 2010-2024 | DVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DaVita receivables for 2023 were
$2.416B
, a
5.28% decline
from 2022.
DaVita receivables for 2022 were
$2.551B
, a
5.81% increase
from 2021.
DaVita receivables for 2021 were
$2.411B
, a
1.16% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Fresenius SE (FSNUY)
$21.7B
Quest Diagnostics (DGX)
$17.3B
Encompass Health (EHC)
$9.6B
Chemed (CHE)
$8.4B
Elanco Animal Health (ELAN)
$6.1B
Option Care Health (OPCH)
$5.3B
RadNet (RDNT)
$5B
LifeStance Health (LFST)
$3.1B
Amedisys (AMED)
$3B
Addus HomeCare (ADUS)
$2.3B
Astrana Health (ASTH)
$2.1B
U.S Physical Therapy (USPH)
$1.3B
Pennant (PNTG)
$945M
Aveanna Healthcare Holdings (AVAH)
$945M
Atai Life Sciences (ATAI)
$252M
Bioqual (BIOQ)
$55M
Daxor (DXR)
$38M
Ontrak (OTRK)
$7M
MEDIROM Healthcare Technologies (MRM)
$4M
IMAC Holdings (BACK)
$2M
Psychemedics (PMD)
$0M